The effects of 2 mg chlormadinone acetate/30 mcg ethinylestradiol, alone or combined with spironolactone, on cardiovascular risk markers in women with polycystic ovary syndrome

Contraception

Volumn 86, Issue 3, 2012, Pages 268-275

  Vieira, Carolina Sales ^a,b   Martins, Wellington P ^a,b,c   Fernandes, Janaína Boldrini França ^a   Soares, Gustavo Mafaldo ^d   Dos Reis, Rosana Maria ^a,b   De Sá, Marcos Felipe Silva ^a,b   Ferriani, Rui Alberto ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b National Institute of Hormones and Women's Health   (Brazil)

^c Escola de Ultrassonografia e Reciclagem Médica de Ribeirão Preto EURP   (Brazil)

^d FEDERAL UNIVERSITY OF RIO GRANDE DO NORTE   (Brazil)

Author keywords

Cardiovascular diseases; Contraceptives; Hormonal; Oral; Polycystic ovary syndrome; Spironolactone

Indexed keywords

CHLORMADINONE ACETATE; CHOLESTEROL; ETHINYLESTRADIOL; SEX HORMONE BINDING GLOBULIN; SPIRONOLACTONE;

ADULT; ARTERIAL STIFFNESS; ARTERIAL WALL THICKNESS; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; BRACHIAL ARTERY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; HUMAN; ORAL CONTRACEPTION; OVARY POLYCYSTIC DISEASE; PHYSICAL ACTIVITY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; VASODILATATION; WAIST CIRCUMFERENCE;

ADULT; BLOOD GLUCOSE; BODY MASS INDEX; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CAROTID ARTERIES; CAROTID INTIMA-MEDIA THICKNESS; CHLORMADINONE ACETATE; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CONTRACEPTIVES, ORAL, COMBINED; DRUG THERAPY, COMBINATION; ETHINYL ESTRADIOL; FEMALE; HUMANS; INSULIN; MINERALOCORTICOID RECEPTOR ANTAGONISTS; POLYCYSTIC OVARY SYNDROME; RISK FACTORS; SEX HORMONE-BINDING GLOBULIN; SPIRONOLACTONE; TESTOSTERONE; TRIGLYCERIDES; VASODILATION;

EID: 84865068292     PISSN: 00107824     EISSN: 18790518     Source Type: Journal    
DOI: 10.1016/j.contraception.2011.12.011     Document Type: Article

References (36)

1. R.J. Norman, D. Dewailly, R.S. Legro, and T.E. Hickey Polycystic ovary syndrome Lancet 370 2007 685 697
2. R. Azziz, K.S. Woods, R. Reyna, T.J. Key, E.S. Knochenhauer, and B.O. Yildiz The prevalence and features of the polycystic ovary syndrome in an unselected population J Clin Endocrinol Metab 89 2004 2745 2749
3. R.A. Wild, E. Carmina, and E. Diamanti-Kandarakis Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society J Clin Endocrinol Metab 95 2010 2038 2049
4. ACOG ACOG Practice Bulletin No. 108: polycystic ovary syndrome Obstet Gynecol 114 2009 936 949
5. G.M. Soares, C.S. Vieira, W. de Paula Martins, R.M. Dos Reis, M.F. de Sa, and R.A. Ferriani Metabolic and cardiovascular impact of oral contraceptives in polycystic ovary syndrome Int J Clin Pract 63 2009 160 169
6. V.A. Gomes, C.S. Vieira, and A.L. Jacob-Ferreira Imbalanced circulating matrix metalloproteinases in polycystic ovary syndrome Mol Cell Biochem 353 2011 251 257
7. M.C. Corretti, T.J. Anderson, and E.J. Benjamin Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force J Am Coll Cardiol 39 2002 257 265
8. D.S. Celermajer, K.E. Sorensen, and V.M. Gooch Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis Lancet 340 1992 1111 1115
9. M.L. Bots, A.W. Hoes, A. Hofman, J.C. Witteman, and D.E. Grobbee Cross-sectionally assessed carotid intima-media thickness relates to long-term risk of stroke, coronary heart disease and death as estimated by available risk functions J Intern Med 245 1999 269 276
10. T. Weber, J. Auer, and M.F. O'Rourke Arterial stiffness, wave reflections, and the risk of coronary artery disease Circulation 109 2004 184 189
11. ESHRE/ASRM Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS) Hum Reprod 19 2004 41 47
12. WHO Medical eligibility criteria for contraceptive use 4th ed. 2010 World Health Organization Geneva
13. W.L. Haskell, I.M. Lee, and R.R. Pate Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association Circulation 116 2007 1081 1093
14. W.T. Friedewald, R.I. Levy, and D.S. Fredrickson Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge Clin Chem 18 1972 499 502
15. D.R. Matthews, J.P. Hosker, A.S. Rudenski, B.A. Naylor, D.F. Treacher, and R.C. Turner Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man Diabetologia 28 1985 412 419
16. P.M. Lizarelli, W.P. Martins, and C.S. Vieira Both a combined oral contraceptive and depot medroxyprogesterone acetate impair endothelial function in young women Contraception 79 2009 35 40
17. W.P. Martins, C.O. Nastri, R.A. Ferriani, and F.M. Filho Brachial artery pulsatility index change 1 minute after 5-minute forearm compression: comparison with flow-mediated dilatation J Ultrasound Med 27 2008 693 699
18. C.O. Nastri, W.P. Martins, R.A. Ferriani, F.M. Filho, and F.J. Dos Reis Sonographic evaluation of endothelial function in letrozole and tamoxifen users Maturitas 61 2008 340 344
19. W.P. Martins, G.M. Soares, C.S. Vieira, R.M. dos Reis, M.F. de Sa, and R.A. Ferriani Cardiovascular risk markers in polycystic ovary syndrome in women with and without insulin resistance Rev Bras Ginecol Obstet 31 2009 111 116
20. W.M. Lijfering, F.R. Rosendaal, and S.C. Cannegieter Risk factors for venous thrombosis - current understanding from an epidemiological point of view Br J Haematol 149 2010 824 833
21. J.P. Baillargeon, D.K. McClish, P.A. Essah, and J.E. Nestler Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis J Clin Endocrinol Metab 90 2005 3863 3870
22. L. Morin-Papunen, H. Martikainen, and M.I. McCarthy Comparison of metabolic and inflammatory outcomes in women who used oral contraceptives and the levonorgestrel-releasing intrauterine device in a general population Am J Obstet Gynecol 199 2008 529.e1 529.e10
23. R.L. Sitruk-Ware, J. Menard, and M. Rad Comparison of the impact of vaginal and oral administration of combined hormonal contraceptives on hepatic proteins sensitive to estrogen Contraception 75 2007 430 437
24. J.N. Lubianca, L.B. Moreira, M. Gus, and F.D. Fuchs Stopping oral contraceptives: an effective blood pressure-lowering intervention in women with hypertension J Hum Hypertens 19 2005 451 455
25. L.M. Lopez, D.A. Grimes, and K.F. Schulz Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus Cochrane Database Syst Rev 2009 CD006133
26. D. Cibula, M. Fanta, and J. Vrbikova The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients Hum Reprod 20 2005 180 184
27. G. Mastorakos, C. Koliopoulos, E. Deligeoroglou, E. Diamanti-Kandarakis, and G. Creatsas Effects of two forms of combined oral contraceptives on carbohydrate metabolism in adolescents with polycystic ovary syndrome Fertil Steril 85 2006 420 427
28. M.E. Safar, and G.M. London Therapeutic studies and arterial stiffness in hypertension: recommendations of the European Society of Hypertension. The Clinical Committee of Arterial Structure and Function. Working Group on Vascular Structure and Function of the European Society of Hypertension J Hypertens 18 2000 1527 1535
29. W.P. Martins, C.O. Nastri, C.S. Vieira, and R.A. Ferriani Flow-mediated dilatation in polycystic ovary syndrome women Fertil Steril e23 2009 91
30. C. Meyer, B.P. McGrath, and H.J. Teede Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome Diabetes Care 30 2007 471 478
31. K.B. Studen, M. Sebestjen, M. Pfeifer, and J. Prezelj Influence of spironolactone treatment on endothelial function in non-obese women with polycystic ovary syndrome Eur J Endocrinol 164 2011 389 395
32. F. Fruzzetti, D. Perini, V. Lazzarini, D. Parrini, M. Gambacciani, and A.R. Genazzani Comparison of effects of 3 mg drospirenone plus 20 mcg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome Fertil Steril 94 2010 1793 1798
33. V. De Leo, A. Di Sabatino, and M.C. Musacchio Effect of oral contraceptives on markers of hyperandrogenism and SHBG in women with polycystic ovary syndrome Contraception 82 2010 276 280
34. S.G. Lakoski, and D.M. Herrington Effects of hormone therapy on C-reactive protein and IL-6 in postmenopausal women: a review article Climacteric 8 2005 317 326
35. G. Mastorakos, C. Koliopoulos, and G. Creatsas Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives Fertil Steril 77 2002 919 927
36. E. Zulian, P. Sartorato, and S. Benedini Spironolactone in the treatment of polycystic ovary syndrome: effects on clinical features, insulin sensitivity and lipid profile J Endocrinol Invest 28 2005 49 53